Cargando…
A role for IL-33–activated ILC2s in eosinophilic vasculitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262498/ https://www.ncbi.nlm.nih.gov/pubmed/33974563 http://dx.doi.org/10.1172/jci.insight.143366 |
_version_ | 1783719200959758336 |
---|---|
author | Kotas, Maya E. Dion, Jérémie Van Dyken, Steven Ricardo-Gonzalez, Roberto R. Danel, Claire J. Taillé, Camille Mouthon, Luc Locksley, Richard M. Terrier, Benjamin |
author_facet | Kotas, Maya E. Dion, Jérémie Van Dyken, Steven Ricardo-Gonzalez, Roberto R. Danel, Claire J. Taillé, Camille Mouthon, Luc Locksley, Richard M. Terrier, Benjamin |
author_sort | Kotas, Maya E. |
collection | PubMed |
description | Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore the mechanism of these findings in patients, we established a model of EGPA in which active vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further study and therapeutic targeting in patients with EGPA. |
format | Online Article Text |
id | pubmed-8262498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-82624982021-07-13 A role for IL-33–activated ILC2s in eosinophilic vasculitis Kotas, Maya E. Dion, Jérémie Van Dyken, Steven Ricardo-Gonzalez, Roberto R. Danel, Claire J. Taillé, Camille Mouthon, Luc Locksley, Richard M. Terrier, Benjamin JCI Insight Research Article Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore the mechanism of these findings in patients, we established a model of EGPA in which active vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further study and therapeutic targeting in patients with EGPA. American Society for Clinical Investigation 2021-06-22 /pmc/articles/PMC8262498/ /pubmed/33974563 http://dx.doi.org/10.1172/jci.insight.143366 Text en © 2021 Kotas et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Kotas, Maya E. Dion, Jérémie Van Dyken, Steven Ricardo-Gonzalez, Roberto R. Danel, Claire J. Taillé, Camille Mouthon, Luc Locksley, Richard M. Terrier, Benjamin A role for IL-33–activated ILC2s in eosinophilic vasculitis |
title | A role for IL-33–activated ILC2s in eosinophilic vasculitis |
title_full | A role for IL-33–activated ILC2s in eosinophilic vasculitis |
title_fullStr | A role for IL-33–activated ILC2s in eosinophilic vasculitis |
title_full_unstemmed | A role for IL-33–activated ILC2s in eosinophilic vasculitis |
title_short | A role for IL-33–activated ILC2s in eosinophilic vasculitis |
title_sort | role for il-33–activated ilc2s in eosinophilic vasculitis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262498/ https://www.ncbi.nlm.nih.gov/pubmed/33974563 http://dx.doi.org/10.1172/jci.insight.143366 |
work_keys_str_mv | AT kotasmayae aroleforil33activatedilc2sineosinophilicvasculitis AT dionjeremie aroleforil33activatedilc2sineosinophilicvasculitis AT vandykensteven aroleforil33activatedilc2sineosinophilicvasculitis AT ricardogonzalezrobertor aroleforil33activatedilc2sineosinophilicvasculitis AT danelclairej aroleforil33activatedilc2sineosinophilicvasculitis AT taillecamille aroleforil33activatedilc2sineosinophilicvasculitis AT mouthonluc aroleforil33activatedilc2sineosinophilicvasculitis AT locksleyrichardm aroleforil33activatedilc2sineosinophilicvasculitis AT terrierbenjamin aroleforil33activatedilc2sineosinophilicvasculitis AT kotasmayae roleforil33activatedilc2sineosinophilicvasculitis AT dionjeremie roleforil33activatedilc2sineosinophilicvasculitis AT vandykensteven roleforil33activatedilc2sineosinophilicvasculitis AT ricardogonzalezrobertor roleforil33activatedilc2sineosinophilicvasculitis AT danelclairej roleforil33activatedilc2sineosinophilicvasculitis AT taillecamille roleforil33activatedilc2sineosinophilicvasculitis AT mouthonluc roleforil33activatedilc2sineosinophilicvasculitis AT locksleyrichardm roleforil33activatedilc2sineosinophilicvasculitis AT terrierbenjamin roleforil33activatedilc2sineosinophilicvasculitis |